Toyohiro Hirai
Kyoto University
371 Papers
1.1K Citations
Toyohiro Hirai is an academic researcher from Kyoto University. The author has contributed to research in topics: Medicine & COPD. The author has an hindex of 39, co-authored 257 publications. Previous affiliations of Toyohiro Hirai include Nagasaki University & Japanese Ministry of Health, Labour and Welfare.
Chat about Author
Papers
Title: A novel cooling system for continuous positive airway pressure therapy: application of a cooling towel
Satoshi Hamada,Jumpei Togawa,Hironobu Sunadome,Naomi Takahashi,Toyohiro Hirai,Susumu Sato +5 more
Subtyping emphysematous COPD by respiratory volume change distributions on CT
Hiroshi Shima,Naoya Tanabe,Akira Oguma,Kaoruko Shimizu,Shizuo Kaji,Kunihiko Terada,Tsuyoshi Oguma,Takeshi Kubo,Masaru Suzuki,Hironi Makita,Atsuyasu Sato,Masaharu Nishimura,Susumu Sato,Satoshi Konno,Toyohiro Hirai +14 more
TL;DR: Lower VDI is associated with severe airflow limitation and higher mortality independent of emphysema severity and airway morphological changes in patients with emphySEmatous COPD.
CT Imaging-Based Low-Attenuation Super Clusters in Three Dimensions and the Progression of Emphysema
Jarred R. Mondoñedo,Susumu Sato,Tsuyoshi Oguma,Shigeo Muro,Adam H. Sonnenberg,Dean Zeldich,Harikrishnan Parameswaran,Toyohiro Hirai,Béla Suki +8 more
TL;DR: Simulations indicated disease progression was more likely to occur near existing emphysematous regions, giving rise to a biomechanical, force‐induced mechanism of super cluster growth.
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer.
Tatsuya Ogimoto,Hiroaki Ozasa,Takahiro Tsuji,Tomoko Funazo,Masatoshi Yamazoe,Kentaro Hashimoto,Hiroshi Yoshida,Kazutaka Hosoya,Hitomi Ajimizu,Takashi Nomizo,Hironori Yoshida,Masatsugu Hamaji,Toshi Menju,Akihiko Yoshizawa,Hiroshi Date,Toyohiro Hirai +15 more
TL;DR: Combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation-positive lung cancer, and the combined effect of VT104 and EGFTKIs and a YAP1-TEAD pathway inhibitor was confirmed.
Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease
Tomohiro Handa,Shoko Matsui,Hajime Yoshifuji,Yuzo Kodama,Hiroshi Yamamoto,Seijiro Minamoto,Yuko Waseda,Yasuharu Sato,Keishi Kubo,Tsuneyo Mimori,Tsutomu Chiba,Toyohiro Hirai,Michiaki Mishima +12 more
TL;DR: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment.